Search Results - "Lluch Hernandez, A"

Preclinical and clinical development of palbociclib and future perspectives by de Dueñas, E. Martínez, Gavila-Gregori, J., Olmos-Antón, S., Santaballa-Bertrán, A., Lluch-Hernández, A., Espinal-Domínguez, E. J., Rivero-Silva, M., Llombart-Cussac, A.

“…Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and…”
Get full text

Subcutaneous trastuzumab: drug development and current position by Martín Martorell, P., Bermejo de las Heras, B., Pérez-Fidalgo, J. A., Huerta Alvaro, M., Martín, M., Albanell, J., Lluch Hernández, A.

“…HER2-positive breast cancer, accounting for 15 % of the total breast cancer patient population, carries in itself a bad prognosis, which has now become much…”
Get full text

Preventive treatments for breast cancer: recent developments by Alés-Martínez, J. E., Ruiz, A., Chacón, J. I., Lluch Hernández, A., Ramos, M., Córdoba, O., Aguirre, E., Barnadas, A., Jara, C., González, S., Plazaola, A., Florián, J., Andrés, R., Sánchez Rovira, P., Frau, A.

“…Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social,…”
Get full text

P301 Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE) by Gianni, L, Pienkowski, T, Im, Y.-H, Roman, L, Tseng, L.-M, Liu, M.-C, Lluch-Hernandez, A, Semiglazov, V, Valagussa, P, Szado, T

Get full text

18P In vitro analysis of the combination of APR-246 and carboplatin in triple negative breast cancer (TNBC) and high grade serous ovarian cancer (HGSOC) cell lines and its impact on Aurora kinase A (AURKA)-p53 pathway by Martinez-Pretel, J.J., Pineda, B., Eguez, K., Ortega Morillo, B., Hochstadt, J., Monzon, M., Lluch-Hernandez, A., Cervantes, A., Perez Fidalgo, J.A.

Get full text

299P MicroRNAs-449 regulate doxorubicin response through ACSL4 modulation in TNBC by Torres Ruiz, S., Garrido Cano, I., Cervera Vidal, R., Hernando Melia, C., Martinez, M.T.M., Zazo, S., Burgués, O., Rojo Todo, F., Bermejo, B., Lluch-Hernandez, A., Cejalvo Andujar, J.M., Eroles, P., Tormo Martin, E.

Get full text

195P A prognostic signature based on two-miRNA and pathological data in early-stage HER2+ breast cancer patients by Artigues, A. Adam, Beltrán, M.Á., Carbonell-Asins, J.A., Zuñiga, S., Moragón, S., Martinez, M.T.M., Hernando Melia, C., O. Burgués, Rojo Todo, F., Albanell Mestres, J., Lluch-Hernandez, A., Bermejo, B., Eroles, P., Cejalvo, J.M.

Get full text

Differential microRNA expression in breast cancer patients aged 35 years or younger by Ribas, G., Peña-Chilet, M., Oltra, S.S., Martinez, M.T., Lluch-Hernandez, A., Ayala, G.

Get full text

270PPROGNOSTIC VALUE OF RESIDUAL DISEASE IN BREAST AND NODES (RDBN), A HISTOPATHOLOGIC SYSTEM TO EVALUATE THE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY (NAC) IN BREAST CANCER by Pons, V., Pérez-Fidalgo, J.A., Burgués, O., Martinez, M.T., Martín, P., Bermejo, B., Cejalvo, J.M., Pinilla, K., Lluch-Hernandez, A.

“…Abstract Aim: Many studies have shown the prognostic value of the complete pathological response after NAC in breast cancer. There are many histopathological…”
Get full text

Prognostic Value of Residual Disease in Breast and Nodes (Rdbn), a Histopathologic System to Evaluate the Response After Neoadjuvant Chemotherapy (Nac) in Breast Cancer by Pons, V., Pérez-Fidalgo, J.A., Burgués, O., Martinez, M.T., Martín, P., Bermejo, B., Cejalvo, J.M., Pinilla, K., Lluch-Hernandez, A.

Get full text

Prospective Evaluation of Two Multi-Gene Assays in Node-Negative, Estrogen Receptor-Positive (Er+) Breast Cancer Patients to Aid Adjuvant Clinical Decision Making in a Community-Based Study by de Dueñas, E. Martinez, Lluch-Hernandez, A., Llombart, A., Rodriguez-Lescure, A., Salas, D., Garcia, J. Miranda

Get full text

282PPROSPECTIVE EVALUATION OF TWO MULTI-GENE ASSAYS IN NODE-NEGATIVE, ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER PATIENTS TO AID ADJUVANT CLINICAL DECISION MAKING IN A COMMUNITY-BASED STUDY by de Dueñas, E. Martinez, Lluch-Hernandez, A., Llombart, A., Rodriguez-Lescure, A., Salas, D., Garcia, J. Miranda

“…Abstract Aim: Gene expression profiles have prognostic value and have led to altered adjuvant systemic therapy recommendations in 25%–30% of breast cancer…”
Get full text

Breast cancer fast-track programme - Evolution and guidelines to prioritize patient referral by Martinez, M.T.M., Gonzalez, I. Chirivella, Pinilla, K., Fernandez, A., Viala, A., Iranzo, A., Caballero, A., Calvete, J., Sanmartin, A., Navarro, J., Bermejo, B., Lluch-Hernandez, A.

Get full text

Long lasting survival (LLS) after removal of primary tumor (PT) in metastatic breast cancer (MBC). Impact of age on outcome by Fidalgo, J.A. Perez, Caballero, A., Cejalvo, J.M., Burgues, O., Hernando, C., Tolosa, P., Iranzo, A., Bermejo, B., Sabio, J.B. Ramirez, Magro, A., Lluch-Hernandez, A.

Get full text

Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up by Martinez, M.T.M., PeÑa-Chilet, M., Oltra, S.S., Perez-Fidalgo, J.A., Alonso, E., Burgues, O., Gonzalez, I. Chirivella, Bermejo, B., Lluch-Hernandez, A., Ribas, G.

Get full text

Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial by Balmaña, J., Cruz, C., Arun, B.K., Telli, M., Garber, J., Domchek, S., Fernandez, C.M., Kahatt, C., Szyldergemajn, S., Soto-Matos, A., Haza, A. Perezdela, Fidalgo, J.A. Perez, Lluch-Hernandez, A., Antolin, S., Tung, N.M., Vahdat, L.T., Lopez, R., Isakoff, S.J.J.

Get full text

Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer by Fernandez, A. Ocana, Templeton, A.J., Casas, M., Sánchez-Aragó, M., Caballero, R., Lescure, A. Rodríguez, Ruiz, A., Alba, E., Calvo, L., Ruiz, M., Santaballa, A., Rodríguez, C., Crespo, C., Ramos, M., Marco, J.M. Gracia, Lluch-Hernandez, A., Alvarez, I., Carrasco, E., Amir, E., Martin, M.

Get full text

1394PBREAST CANCER FAST-TRACK PROGRAMME TO SHORTEN TIME BETWEEN INITIAL SYMPTOMS, DIAGNOSIS AND INITIATION OF TREATMENT by Martinez, M.T., Gonzalez, I. Chirivella, Gonzalez, I., Pinilla, K., Fernandez, A., Martinez-Agullo, A., Caballero, A., Saiz, R., Martorell, P. Martin, Bermejo, B., Lluch-Hernandez, A.

“…Abstract Aim: Cancer is one of the most serious health problems worldwide. The implementation of screening programs and diagnostic and therapeutic advances…”
Get full text

Breast Cancer Fast-Track Programme to Shorten Time Between Initial Symptoms, Diagnosis and Initiation of Treatment by Martinez, M.T., Gonzalez, I. Chirivella, Gonzalez, I., Pinilla, K., Fernandez, A., Martinez-Agullo, A., Caballero, A., Saiz, R., Martorell, P. Martin, Bermejo, B., Lluch-Hernandez, A.

Get full text

Germline genetic background contribution to metastatic dissemination in breast cancer extreme phenotype patients by Santonja, A., Pajares, B., Jiménez-Rodríguez, B., Sousa, C. Fernández-De, Ribelles, N., Lluch-Hernandez, A., Catoira, I., Perez-Ruiz, E., Martin, M., Del Monte-Millan, M., Gonzalez-Neira, A., Pita, G., Pujana, M.A., Ruiz, M., Bonifaci, N., De la Haba, J., Sanchez-Rovira, P., Alba, E., Romero, A.

Get full text